Previous close | 1.9300 |
Open | 1.8900 |
Bid | 1.8200 x 1400 |
Ask | 1.9200 x 1200 |
Day's range | 1.8900 - 1.9000 |
52-week range | 0.3500 - 5.2000 |
Volume | |
Avg. volume | 6,623,124 |
Market cap | 59.806M |
Beta (5Y monthly) | 1.42 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.5480 |
Earnings date | 10 Nov 2022 - 14 Nov 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 20 Aug 2015 |
1y target est | 16.00 |
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second quarter ended June 30, 2022. “We were very pleased to have completed the sale of our complement portfolio during the second quarter to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (“Vertex”) for $60.0 million in cash with up to $5.0 million of that amount due in May 2023. This transaction was the
FORT LEE, N.J., August 11, 2022--JDS1, LLC ("JDS1"), which collectively with the other reporting persons in its Section 13(d) group, beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Biosciences, Inc. (NASDAQ: CBIO) ("Catalyst" or the "Company"), commented today on its previously announced withdrawal of the director nominations and other proposed business that it had intended to bring before the upcoming 2022 Annual Meeting of Stockholders of Catalyst Biosciences,
Encourages Stockholders to Vote on the WHITE Proxy CardSOUTH SAN FRANCISCO, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company,” “Catalyst” or “we”) announced that it has received a notice from JDS1, LLC (“JDS1”) that JDS1 has withdrawn the nominations of Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn (the “Withdrawn Candidates”) for election to the Catalyst Board of Directors at the Catalyst 2022 annual meeting of stockholders (the “2022 An